Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNUM4K)

Drug Name
3-hydroxybenzylhydrazine Drug Info
Synonyms
3-hydroxybenzylhydrazine; 3-(hydrazinylmethyl)phenol; 637-33-2; 3-(Hydrazinomethyl)phenol; Nsd 1015; m-Hydroxybenzyl hydrazine; UNII-A27K5Q85R2; 3-Hydrazinomethyl-phenol; BRN 1841459; HYDRAZINE, 1-(3-HYDROXYBENZYL)-; CHEMBL352205; NSD-1015; A27K5Q85R2; 3-hydroxy-benzylhydrazine; C7H10N2O; m-hydroxybenzylhydrazine; Phenol,3-(hydrazinylmethyl)-; Spectrum_000313; SpecPlus_000785; AC1L1BYI; Spectrum4_001209; Spectrum5_001883; Spectrum3_000726; Lopac-H-9382; Lopac0_000597; BSPBio_002252; KBioGR_001618; 3-(Hydrazinomethyl)phenol #
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1663
ChEBI ID
CHEBI:104133
CAS Number
CAS 637-33-2
TTD Drug ID
DMNUM4K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Aromatic-L-amino-acid decarboxylase (DDC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin B6 DMDBZMV Vitamin B6 deficiency 5B5D Approved [3]
Carbidopa DMHRG8Q Parkinson disease 8A00.0 Approved [4]
Patrome DM3H2U4 Parkinson disease 8A00.0 Phase 3 [5]
Benserazide DMLU8NX N. A. N. A. Phase 3 [4]
AV-201 DMDL9WU Parkinson disease 8A00.0 Phase 2 [6]
VY-AADC DMPSBTL Parkinson disease 8A00.0 Phase 2 [7]
GT-AADC DM8N3OQ Aromatic L-amino acid decarboxylase deficiency 5C59.00 Phase 2 [8]
PTC-AADC DM9ZHE3 Aromatic L-amino acid decarboxylase deficiency 5C59.00 Phase 2 [9]
ProSavin DMJ42E6 Parkinson disease 8A00.0 Phase 1/2 [10]
OXB-102 DMXF9DM Parkinson disease 8A00.0 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatic-L-amino-acid decarboxylase (DDC) TTN451K DDC_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5116).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1271).
3 Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
4 Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
5 The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
6 UCSF report
7 Clinical pipeline report, company report or official report of Voyager Therapeutics.
8 Clinical pipeline report, company report or official report of PTC Therapeutics.
9 ClinicalTrials.gov (NCT04903288) An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects. U.S.National Institutes of Health.
10 Clinical pipeline report, company report or official report of Oxford BioMedica.
11 Clinical pipeline report, company report or official report of Oxford BioMedica.